These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
370 related articles for article (PubMed ID: 22810899)
1. Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas. Johnson ML; Sima CS; Chaft J; Paik PK; Pao W; Kris MG; Ladanyi M; Riely GJ Cancer; 2013 Jan; 119(2):356-62. PubMed ID: 22810899 [TBL] [Abstract][Full Text] [Related]
2. Differences in the survival of patients with recurrent versus de novo metastatic KRAS-mutant and EGFR-mutant lung adenocarcinomas. Yu HA; Sima CS; Hellmann MD; Naidoo J; Busby N; Rodriguez K; Riely GJ; Kris MG Cancer; 2015 Jun; 121(12):2078-82. PubMed ID: 25781862 [TBL] [Abstract][Full Text] [Related]
3. Driver mutations determine survival in smokers and never-smokers with stage IIIB/IV lung adenocarcinomas. Paik PK; Johnson ML; D'Angelo SP; Sima CS; Ang D; Dogan S; Miller VA; Ladanyi M; Kris MG; Riely GJ Cancer; 2012 Dec; 118(23):5840-7. PubMed ID: 22605530 [TBL] [Abstract][Full Text] [Related]
4. Clinicopathologic and prognostic significance of c-MYC copy number gain in lung adenocarcinomas. Seo AN; Yang JM; Kim H; Jheon S; Kim K; Lee CT; Jin Y; Yun S; Chung JH; Paik JH Br J Cancer; 2014 May; 110(11):2688-99. PubMed ID: 24809777 [TBL] [Abstract][Full Text] [Related]
5. Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers. Dogan S; Shen R; Ang DC; Johnson ML; D'Angelo SP; Paik PK; Brzostowski EB; Riely GJ; Kris MG; Zakowski MF; Ladanyi M Clin Cancer Res; 2012 Nov; 18(22):6169-77. PubMed ID: 23014527 [TBL] [Abstract][Full Text] [Related]
6. Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib. D'Angelo SP; Janjigian YY; Ahye N; Riely GJ; Chaft JE; Sima CS; Shen R; Zheng J; Dycoco J; Kris MG; Zakowski MF; Ladanyi M; Rusch V; Azzoli CG J Thorac Oncol; 2012 Dec; 7(12):1815-1822. PubMed ID: 23154553 [TBL] [Abstract][Full Text] [Related]
7. Lungs don't forget: Comparison of the KRAS and EGFR mutation profile and survival of collegiate smokers and never smokers with advanced lung cancers. Varghese AM; Sima CS; Chaft JE; Johnson ML; Riely GJ; Ladanyi M; Kris MG J Thorac Oncol; 2013 Jan; 8(1):123-5. PubMed ID: 23242442 [TBL] [Abstract][Full Text] [Related]
8. Impact of KRAS and EGFR gene mutations on recurrence and survival in patients with surgically resected lung adenocarcinomas. Sonobe M; Kobayashi M; Ishikawa M; Kikuchi R; Nakayama E; Takahashi T; Menju T; Takenaka K; Miyahara R; Huang CL; Okubo K; Bando T; Date H Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S347-54. PubMed ID: 21607772 [TBL] [Abstract][Full Text] [Related]
9. The impact of cigarette smoking on the frequency of and qualitative differences in KRAS mutations in Korean patients with lung adenocarcinoma. Kim HR; Ahn JR; Lee JG; Bang DH; Ha SJ; Hong YK; Kim SM; Nam KC; Rha SY; Soo RA; Riely GJ; Kim JH; Cho BC Yonsei Med J; 2013 Jul; 54(4):865-74. PubMed ID: 23709419 [TBL] [Abstract][Full Text] [Related]
10. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2). Cadranel J; Mauguen A; Faller M; Zalcman G; Buisine MP; Westeel V; Longchampt E; Wislez M; Coudert B; Daniel C; Chetaille B; Michiels S; Blons H; Solassol J; De Fraipont F; Foucher P; Urban T; Lacroix L; Poulot V; Quoix E; Antoine M; Danton G; Morin F; Chouaid C; Pignon JP J Thorac Oncol; 2012 Oct; 7(10):1490-502. PubMed ID: 22982650 [TBL] [Abstract][Full Text] [Related]
11. Subtype-specific KRAS mutations in advanced lung adenocarcinoma: a retrospective study of patients treated with platinum-based chemotherapy. Cserepes M; Ostoros G; Lohinai Z; Raso E; Barbai T; Timar J; Rozsas A; Moldvay J; Kovalszky I; Fabian K; Gyulai M; Ghanim B; Laszlo V; Klikovits T; Hoda MA; Grusch M; Berger W; Klepetko W; Hegedus B; Dome B Eur J Cancer; 2014 Jul; 50(10):1819-1828. PubMed ID: 24768329 [TBL] [Abstract][Full Text] [Related]
12. KRAS Mutation Is a Significant Prognostic Factor in Early-stage Lung Adenocarcinoma. Kadota K; Sima CS; Arcila ME; Hedvat C; Kris MG; Jones DR; Adusumilli PS; Travis WD Am J Surg Pathol; 2016 Dec; 40(12):1579-1590. PubMed ID: 27740967 [TBL] [Abstract][Full Text] [Related]
13. Cytomorphologic features of advanced lung adenocarcinomas tested for EGFR and KRAS mutations: a retrospective review of 50 cases. Marotti JD; Schwab MC; McNulty NJ; Rigas JR; DeLong PA; Memoli VA; Tsongalis GJ; Padmanabhan V Diagn Cytopathol; 2013 Jan; 41(1):15-21. PubMed ID: 21681971 [TBL] [Abstract][Full Text] [Related]
14. Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose. Li H; Pan Y; Li Y; Li C; Wang R; Hu H; Zhang Y; Ye T; Wang L; Shen L; Sun Y; Chen H Lung Cancer; 2013 Jan; 79(1):8-13. PubMed ID: 23098378 [TBL] [Abstract][Full Text] [Related]
15. Validation of the IASLC/ATS/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations: analysis of 440 Japanese patients. Yoshizawa A; Sumiyoshi S; Sonobe M; Kobayashi M; Fujimoto M; Kawakami F; Tsuruyama T; Travis WD; Date H; Haga H J Thorac Oncol; 2013 Jan; 8(1):52-61. PubMed ID: 23242438 [TBL] [Abstract][Full Text] [Related]
17. Epidermal growth factor receptor and KRAS mutations in lung adenocarcinoma: a retrospective study of the Lebanese population. Fakhruddin N; Mahfouz R; Farhat F; Tfayli A; Abdelkhalik R; Jabbour M; Yehia L; Mahfoud Z; Zaatari G Oncol Rep; 2014 Nov; 32(5):2223-9. PubMed ID: 25120214 [TBL] [Abstract][Full Text] [Related]
18. Mutational Profile and New IASLC/ATS/ERS Classification Provide Additional Prognostic Information about Lung Adenocarcinoma: A Study of 125 Patients from Brazil. de Melo AC; Karen de Sá V; Sternberg C; Olivieri ER; Werneck da Cunha I; Fabro AT; Carraro DM; de Barros e Silva MJ; Pimenta Inada HK; de Mello ES; Soares FA; Takagaki T; Ferreira CG; Capelozzi VL Oncology; 2015; 89(3):175-86. PubMed ID: 25833149 [TBL] [Abstract][Full Text] [Related]
19. Clinicopathological predictors of EGFR/KRAS mutational status in primary lung adenocarcinomas. Dacic S; Shuai Y; Yousem S; Ohori P; Nikiforova M Mod Pathol; 2010 Feb; 23(2):159-68. PubMed ID: 19855375 [TBL] [Abstract][Full Text] [Related]
20. Non-terminal respiratory unit type lung adenocarcinoma has three distinct subtypes and is associated with poor prognosis. Sumiyoshi S; Yoshizawa A; Sonobe M; Kobayashi M; Sato M; Fujimoto M; Tsuruyama T; Date H; Haga H Lung Cancer; 2014 Jun; 84(3):281-8. PubMed ID: 24725383 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]